Prudential Financial Inc. purchased a new stake in CareDx Inc (NASDAQ:CDNA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 52,166 shares of the company’s stock, valued at approximately $1,877,000. Prudential Financial Inc. owned 0.12% of CareDx at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Aperio Group LLC purchased a new position in shares of CareDx during the 2nd quarter worth approximately $31,000. First Quadrant L P CA purchased a new position in shares of CareDx during the 2nd quarter worth approximately $63,000. Private Wealth Partners LLC purchased a new position in shares of CareDx during the 2nd quarter worth approximately $216,000. Steward Partners Investment Advisory LLC purchased a new position in shares of CareDx during the 2nd quarter worth approximately $222,000. Finally, Ibex Investors LLC purchased a new position in shares of CareDx during the 2nd quarter worth approximately $232,000. 92.49% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Sasha King sold 9,542 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $35.74, for a total value of $341,031.08. Following the sale, the insider now directly owns 62,045 shares in the company, valued at approximately $2,217,488.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Maag sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $28.84, for a total transaction of $1,442,000.00. Following the completion of the sale, the chief executive officer now owns 379,049 shares in the company, valued at $10,931,773.16. The disclosure for this sale can be found here. 3.20% of the stock is owned by corporate insiders.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of CareDx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Raymond James increased their price objective on shares of CareDx from $46.00 to $48.00 and gave the stock a “strong-buy” rating in a research report on Friday, August 2nd. Piper Jaffray Companies set a $63.00 price objective on shares of CareDx and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Craig Hallum set a $48.00 price objective on shares of CareDx and gave the stock a “positive” rating in a research report on Thursday, July 11th. Finally, TheStreet cut shares of CareDx from a “c” rating to a “d” rating in a research report on Thursday, May 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.00.

CareDx stock traded up $0.51 during mid-day trading on Thursday, reaching $24.38. 10,315 shares of the company’s stock were exchanged, compared to its average volume of 749,982. The company has a market cap of $1.00 billion, a P/E ratio of -18.56 and a beta of 1.04. CareDx Inc has a twelve month low of $19.11 and a twelve month high of $41.27. The company has a fifty day moving average of $24.86 and a 200-day moving average of $31.05.

CareDx (NASDAQ:CDNA) last released its earnings results on Thursday, August 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The business had revenue of $31.45 million for the quarter, compared to analyst estimates of $27.96 million. CareDx had a negative return on equity of 47.53% and a negative net margin of 38.29%. Equities research analysts forecast that CareDx Inc will post -0.7 earnings per share for the current year.

CareDx Profile

CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Featured Story: Is a Roth IRA right for you?

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.